AstraZeneca's Imfinzi wins US approval for gastroesophageal cancer
(Alliance News) - AstraZeneca PLC on Tuesday said Imfinzi has been approved in the US as the first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers. Read More